Didanosine/Hydroxyurea Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

When these two medicines are taken together, hydroxyurea may increase the risk of side effects from didanosine.

What might happen:

The side effects of didanosine, including pancreatitis (a dangerous inflammation of the pancreas), peripheral neuropathy (a problem with the nerves in the hands and feet), and liver problems may be more common in patients who take didanosine with hydroxyurea. The symptoms of pancreatitis include stomach pain, nausea, or vomiting. The symptoms of peripheral neuropathy include loss of feeling, weakness, tingling or pain in your hands and/or feet. The symptoms of liver problems include abdominal pain and yellowing of the eyes and/or skin. If you also take stavudine, the risk of these effects may be even greater.

What you should do about this interaction:

Make sure your health care professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to check the amount of didanosine in your blood to make sure that you are getting the right amount. Your doctor may need to change the dose of your medicines. Let your doctor know right away if you have any stomach pain, nausea, vomiting, or loss of feeling, weakness, tingling or pain in your hands and/or feet.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Longhurst HJ, Pinching AJ. Drug Points: pancreatitis associated with hydroxyurea in combination with didanosine. BMJ 2001 Jan 13;322(7278):81.
  • 2.Videx EC (didanosine) US prescribing information. Bristol-Myers Squibb Company January 25, 2018.
  • 3.Hydrea (hydroxyurea) US prescribing information. Bristol-Myers Squibb Company December 18, 2017.
  • 4.Moore RD, Wong WM, Keruly JC, McArthur JC. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS 2000 Feb 18;14(3):273-8.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.